Biopharmaceuticals Growing Twice as Fast as Pharmaceuticals

IMARC Group, one of the world's leading research and advisory firms, finds in its new report “Global Biopharmaceutical Market Report & Forecast: 2012-2017” that with a share of nearly 48%, the US represents the world’s biggest biopharmaceutical market. Findings from the report suggest that although the growth of biopharmaceuticals in the country has declined in recent years, the market is still growing twice as fast as the pharmaceutical market.

The report which has done a comprehensive qualitative and quantitative analysis on the global biopharmaceutical market, finds that recombinant proteins currently dominate the US biopharmaceutical market with insulin representing the biggest class in this segment. Monoclonal antibodies, however, represent the most lucrative segment in the US biopharmaceutical market with its total sales growing at a CAGR of nearly 17% during 2005 - 2011.

Findings from the report, which has done an in-depth analysis of the competitive landscapes of all major biopharmaceutical markets, finds that there are currently more than 50 biopharmaceutical companies operating in the US with Amgen being the biggest player. Roche currently represents the fastest growing biopharmaceutical player in the US and is expected to overtake Amgen over the next few years.

IMARC’s new report “Global Biopharmaceutical Market Report & Forecast: 2012-2017” gives a deep insight into the global biopharmaceutical market. The research study serves as an analytical as well as a statistical tool to understand the strengths, weaknesses, opportunities, threats, market trends, geographical structure, therapeutic structure, competitive structure and the outlook of the global biopharmaceutical market till 2017. This report can serve as an excellent guide for investors, researchers, consultants, marketing strategists, and all those who are planning to foray into the global biopharmaceutical market in some form or the other.

Table of Contents
1. Market Definitions & Research Methodology
2. Analyst Briefing
3. Introduction to Biopharmaceuticals
4. Global Biopharmaceutical Market: Industry Analysis
4.1 Strengths
4.1.1 High Efficacy and Target Oriented Attack
4.1.2 Strong Potential to Achieve Blockbuster Status
4.1.3 Limited Generic Threat
4.1.4 Approval Success Rates are Higher than Small Molecule Drugs
4.2 Weaknesses
4.2.1 Inconvenient Drug Delivery Coupled with Short Half Lives
4.2.2 Second Line of Therapy
4.2.3 Huge Cost of Therapy
4.2.4 High Incidence of Unfavorable Side Effects
4.3 Opportunities
4.3.1 Diseases with High Unmet Needs
4.3.2 Expanding the Patient Pool by Approval into Additional Indications
4.3.3 Emerging Markets
4.3.4 Increasing New Approvals and a Strong Pipeline
4.4 Threats
4.4.1 Biopharmaceutical Drug Development is a Very Risky Venture
4.4.2 Biosimilars
4.4.3 Limited and Conditional Reimbursement
4.4.4 Uncertainties in the Economic Environment
5. Global Biopharmaceutical Market: Industry Performance
5.1 Market Performance & Forecast
5.1.1 Current Performance (2005-2011)
5.1.2 Market Forecast (2012-2017)
5.2 Market Segmentation by Region
5.2.1 Current Performance (2005-2011)
5.2.2 Market Forecast (2012-2017)
5.3 Market Segmentation by Indication
5.4 Market Segmentation by Class
5.4.1 Recombinant Proteins
5.4.2 Monoclonal Antibodies
5.4.3 Purified Proteins
5.5 Competitive Landscape
5.5.1 Top Biopharmaceutical Players
5.5.2 Top Biopharmaceutical Drugs
6. North America
6.1 US
6.1.1 Market Performance (2005-2011)
6.1.2 Market Segmentation by Class
6.1.3 Performance of Top Players
6.1.4 Market Forecast (2012-2017)
6.2 Canada
6.2.1 Market Performance (2005-2011)
6.2.2 Market Segmentation by Class
6.2.3 Performance of Top Players
6.2.4 Market Forecast (2012-2017)
7. Latin America
7.1 Mexico
7.1.1 Market Performance (2005-2011)
7.1.2 Market Segmentation by Class
7.1.3 Performance of Top Players
7.1.4 Market Forecast (2012-2017)
7.2 Brazil
7.2.1 Market Performance (2005-2011)
7.2.2 Market Segmentation by Class
7.2.3 Performance of Top Players
7.2.4 Market Forecast (2012-2017)
7.3 Argentina
7.3.1 Market Performance (2005-2011)
7.3.2 Market Segmentation by Class
7.3.3 Performance of Top Players
7.3.4 Market Forecast (2012-2017)
8. Europe
8.1 Germany
8.1.1 Market Performance (2005-2011)
8.1.2 Market Segmentation by Class
8.1.3 Performance of Top Players
8.1.4 Market Forecast (2012-2017)
8.2 France
8.2.1 Market Performance (2005-2011)
8.2.2 Market Segmentation by Class
8.2.3 Performance of Top Players
8.2.4 Market Forecast (2012-2017)
8.3 Italy
8.3.1 Market Performance (2005-2011)
8.3.2 Market Segmentation by Class
8.3.3 Performance of Top Players
8.3.4 Market Forecast (2012-2017)
8.4 Spain
8.4.1 Market Performance (2005-2011)
8.4.2 Market Segmentation by Class
8.4.3 Performance of Top Players
8.4.4 Market Forecast (2012-2017)
8.5 UK
8.5.1 Market Performance (2005-2011)
8.5.2 Market Segmentation by Class
8.5.3 Performance of Top Players
8.5.4 Market Forecast (2012-2017)
8.6 Russia
8.6.1 Market Performance (2005-2011)
8.6.2 Market Segmentation by Class
8.6.3 Performance of Top Players
8.6.4 Market Forecast (2012-2017)
8.7 Turkey
8.7.1 Market Performance (2005-2011)
8.7.2 Market Segmentation by Class
8.7.3 Performance of Top Players
8.7.4 Market Forecast (2012-2017)
9. Asia Pacific
9.1 Japan
9.1.1 Market Performance (2005-2011)
9.1.2 Market Segmentation by Class
9.1.3 Performance of Top Players
9.1.4 Market Forecast (2012-2017)
9.2 China
9.2.1 Market Performance (2005-2011)
9.2.2 Market Segmentation by Class
9.2.3 Performance of Top Players
9.2.4 Market Forecast (2012-2017)
9.3 Australia
9.3.1 Market Performance (2005-2011)
9.3.2 Market Segmentation by Class
9.3.3 Performance of Top Players
9.3.4 Market Forecast (2012-2017)
9.4 South Korea
9.4.1 Market Performance (2005-2011)
9.4.2 Market Segmentation by Class
9.4.3 Performance of Top Players
9.4.4 Market Forecast (2012-2017)
9.6 India
9.6.1 Market Performance (2005-2011)
9.6.2 Market Segmentation by Class
9.6.3 Performance of Top Players
9.6.4 Market Forecast (2012-2017)
9.7 Indonesia
9.7.1 Market Performance (2005-2011)
9.7.2 Market Segmentation by Class
9.7.3 Performance of Top Players
9.7.4 Market Forecast (2012-2017)

To buy the complete report or to get a free sample, please contact:
IMARC Group - Asia
Email: apac@imarcgroup.com
Phone: +91-120-415-5099
IMARC Group - Europe, Middle East & Africa
Email: ema@imarcgroup.com
Phone: +44-702-409-7331
IMARC Group - Europe, Middle East & Africa
Email: america@imarcgroup.com
Phone: +1-631-791-1145

For more than 5 years, the International Market Analysis Research and Consulting Group has been a leading advisor on management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

Ansal Plaza Vaishali, Ghaziabad, India - 201010

This release was published on openPR.